Get to know our clinical trials

Clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of AFM24 in combination with atezolizumab in patients with selected EGFR-expressing advanced/metastatic cancer.

THE OBJECTIVE OF THE STUDY IS TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) AND/OR SELECT ONE OR MORE RECOMMENDED DOSES IN PHASE 2 (DRF2) OF AFM24 IN COMBINATION WITH ATEZOLIZUMAB.

Imagen del Dr. Mariano Ponz Sarvise, oncólogo médico de la Clínica Universidad de Navarra
Dr. Mariano Ponz-Sarvisé Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Gastrointestinal Cancer Area
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 1/2A, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF AFM24 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED EGFR-EXPRESSING ADVANCED/METASTATIC CANCER. IMMUNOTHERAPY.
  • Code EudraCT: 2021-000707-20
  • Protocol number: AFM24-102
  • Promoter: Affimed GmbH

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION